This company has been marked as potentially delisted and may not be actively trading. Sinovac Biotech (SVA) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsDividendFDA EventsHeadlinesOptions ChainOwnershipTrendsBuy This Stock SVA vs. KNSA, TARS, LQDA, ALVO, FOLD, IBRX, DNLI, AGIO, CELC, and HRMYShould you be buying Sinovac Biotech stock or one of its competitors? The main competitors of Sinovac Biotech include Kiniksa Pharmaceuticals International (KNSA), Tarsus Pharmaceuticals (TARS), Liquidia Technologies (LQDA), Alvotech (ALVO), Amicus Therapeutics (FOLD), ImmunityBio (IBRX), Denali Therapeutics (DNLI), Agios Pharmaceuticals (AGIO), Celcuity (CELC), and Harmony Biosciences (HRMY). These companies are all part of the "med - biomed/gene" industry. Sinovac Biotech vs. Its Competitors Kiniksa Pharmaceuticals International Tarsus Pharmaceuticals Liquidia Technologies Alvotech Amicus Therapeutics ImmunityBio Denali Therapeutics Agios Pharmaceuticals Celcuity Harmony Biosciences Kiniksa Pharmaceuticals International (NASDAQ:KNSA) and Sinovac Biotech (NASDAQ:SVA) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, analyst recommendations, dividends, media sentiment and earnings. Do insiders and institutionals hold more shares of KNSA or SVA? 54.0% of Kiniksa Pharmaceuticals International shares are owned by institutional investors. 53.5% of Kiniksa Pharmaceuticals International shares are owned by insiders. Comparatively, 12.8% of Sinovac Biotech shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has more risk & volatility, KNSA or SVA? Kiniksa Pharmaceuticals International has a beta of 0.2, indicating that its stock price is 80% less volatile than the S&P 500. Comparatively, Sinovac Biotech has a beta of 0.68, indicating that its stock price is 32% less volatile than the S&P 500. Do analysts recommend KNSA or SVA? Kiniksa Pharmaceuticals International presently has a consensus price target of $41.17, suggesting a potential upside of 13.63%. Given Kiniksa Pharmaceuticals International's stronger consensus rating and higher probable upside, research analysts plainly believe Kiniksa Pharmaceuticals International is more favorable than Sinovac Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kiniksa Pharmaceuticals International 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Sinovac Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media prefer KNSA or SVA? In the previous week, Kiniksa Pharmaceuticals International had 21 more articles in the media than Sinovac Biotech. MarketBeat recorded 22 mentions for Kiniksa Pharmaceuticals International and 1 mentions for Sinovac Biotech. Kiniksa Pharmaceuticals International's average media sentiment score of 0.83 beat Sinovac Biotech's score of 0.00 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the media. Company Overall Sentiment Kiniksa Pharmaceuticals International Positive Sinovac Biotech Neutral Is KNSA or SVA more profitable? Kiniksa Pharmaceuticals International has a net margin of 0.90% compared to Sinovac Biotech's net margin of 0.00%. Kiniksa Pharmaceuticals International's return on equity of 1.05% beat Sinovac Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Kiniksa Pharmaceuticals International0.90% 1.05% 0.80% Sinovac Biotech N/A N/A N/A Which has preferable valuation & earnings, KNSA or SVA? Kiniksa Pharmaceuticals International has higher earnings, but lower revenue than Sinovac Biotech. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKiniksa Pharmaceuticals International$423.24M6.34-$43.19M$0.04905.75Sinovac Biotech$448.27M1.44-$99.92MN/AN/A SummaryKiniksa Pharmaceuticals International beats Sinovac Biotech on 12 of the 14 factors compared between the two stocks. Get Sinovac Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for SVA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SVA vs. The Competition Export to ExcelMetricSinovac BiotechMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$644.66M$3.18B$5.83B$10.07BDividend YieldN/A2.26%5.25%4.53%P/E RatioN/A21.3175.5726.01Price / Sales1.44453.06536.77117.75Price / Cash38.9545.8737.4259.95Price / Book0.059.6011.536.20Net Income-$99.92M-$53.33M$3.29B$270.65M Sinovac Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SVASinovac BiotechN/A$6.47flatN/AN/A$644.66M$448.27M0.003,261High Trading VolumeKNSAKiniksa Pharmaceuticals International3.1115 of 5 stars$33.90+1.2%$41.17+21.4%+53.3%$2.51B$423.24M847.64220Analyst UpgradeInsider TradeTARSTarsus Pharmaceuticals2.4948 of 5 stars$58.69+0.2%$66.67+13.6%+80.8%$2.48B$182.95M-25.1950Positive NewsInsider TradeLQDALiquidia Technologies3.495 of 5 stars$28.45+2.8%$32.11+12.9%+201.8%$2.45B$14M-16.7550Positive NewsALVOAlvotech2.8015 of 5 stars$7.87-2.5%$14.00+77.9%-26.9%$2.38B$491.98M34.261,032Positive NewsFOLDAmicus Therapeutics4.0749 of 5 stars$7.71+1.5%$16.22+110.5%-31.5%$2.37B$528.29M-64.20480Positive NewsIBRXImmunityBio2.8328 of 5 stars$2.36+0.6%$10.75+356.5%-27.6%$2.23B$56.60M-4.91590Analyst ForecastDNLIDenali Therapeutics4.3497 of 5 stars$15.12-1.0%$33.62+122.4%-40.0%$2.21B$330.53M-5.40430News CoveragePositive NewsAnalyst ForecastHigh Trading VolumeAGIOAgios Pharmaceuticals4.2463 of 5 stars$37.91+0.5%$56.33+48.6%-17.7%$2.20B$36.50M3.45390Insider TradeAnalyst RevisionCELCCelcuity1.4374 of 5 stars$51.89+1.3%$56.50+8.9%+299.0%$2.20BN/A-15.0440News CoveragePositive NewsShort Interest ↑HRMYHarmony Biosciences4.5382 of 5 stars$37.24+0.9%$51.00+37.0%-7.8%$2.15B$714.73M12.03200Positive News Related Companies and Tools Related Companies KNSA Alternatives TARS Alternatives LQDA Alternatives ALVO Alternatives FOLD Alternatives IBRX Alternatives DNLI Alternatives AGIO Alternatives CELC Alternatives HRMY Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SVA) was last updated on 9/10/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: The Plot to Seize Your Cash?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredWall Street Legend Names #1 ‘Hidden’ AI Stock50-year Wall Street legend says to forget NVDA. For the biggest potential gains, it's time to move your money ...Chaikin Analytics | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sinovac Biotech, Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sinovac Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SVA Stock Alerts